Randomization was conducted using an interactive web response system, assigning participants in a 6:1 ratio to one of several treatment arms: once-weekly subcutaneous Cagrilintide administered in doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg, once-daily liraglutide 3.0 mg, or a volume-matched placebo
Neither medication is currently listed as definitively compatible with breastfeeding by major lactation reference databases
This approach works best for patients who experience significant side effects on full-strength weekly dosing or prefer a gentler initiation
Due to its copper content, the peptide may appear in varying shades of blue without affecting consistency or analytical profile
Zhou L, Podolsky N, Sang Z, et al